Currently submitted to: JMIR Research Protocols
Date Submitted: Jun 16, 2026
Open Peer Review Period: Jun 17, 2026 - Aug 12, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Protocol: A Randomized Trial of Shenye Xiaozheng Formula for Chronic Atrophic Gastritis with Low-Grade Dysplasia (SYXZ-CAG Trial)
ABSTRACT
Background:
Chronic atrophic gastritis(CAG) is a prevalent digestive system disorder, and patients presenting with low-grade dysplasia(LGD) face a significantly elevated risk of malignant transformation. Current clinical management primarily relies on regular endoscopic surveillance, as no definitive treatment addressing the underlying pathogenesis or effectively reversing disease progression has been established. Traditional Chinese Medicine(TCM) has demonstrated distinct advantages in managing CAG. This study aims to evaluate the clinical efficacy and safety of Shenye Xiaozheng Formula(SYXZ), a compound Chinese herbal formula, in treating CAG with LGD.
Objective:
This study aims to evaluate the clinical efficacy and safety of Shenye Xiaozheng Formula (SYXZ) in treating chronic atrophic gastritis (CAG) with low-grade dysplasia (LGD), and to provide high-level evidence supporting its clinical application.
Methods:
This multicenter, randomized, double-blind, placebo-controlled clinical trial will enroll 280 participants equally randomized to receive either SYXZ granules or its matched placebo (SYXZ granules simulator) for a 24-week intervention period, followed by 24 weeks of post-treatment follow-up. The primary endpoints are histopathological reversal and progression rates of gastric dysplasia, evaluated through standardized pathological review. Secondary outcomes include changes in serum biomarkers, TCM syndrome scores, endoscopic gastric cancer risk score, OLGA/OLGIM, as well as longitudinal assessments of psychological status (anxiety/depression scales) and systemic inflammatory markers to comprehensively evaluate therapeutic effects and potential mechanisms. A multi-center, randomized, double-blind, placebo-controlled clinical trial will be established. A total of 280 participants in 4 centers with CAG with LGD and TCM syndrome of liver depression and blood stasis This multicenter, randomized, double-blind, placebo-controlled clinical trial will enroll 280 participants with chronic atrophic gastritis accompanied by low-grade dysplasia and liver depression-blood stasis syndrome (as per TCM diagnosis) across four centers. Participants were randomly allocated in a 1:1 ratio to receive either Shenye Xiaozheng granule or its matched placebo for 24 weeks of intervention, followed by 24 weeks of observation. Primary endpoints included histological regression and progression rates of gastric dysplasia. Secondary endpoints comprised serological parameters, TCM syndrome scores, endoscopic gastric cancer risk assessment (OLGA/OLGIM staging), along with evaluations of anxiety/depression scales and inflammatory biomarkers to elucidate potential mechanisms.
Results:
This multicenter, randomized, double-blind, placebo-controlled trial will rigorously assess the histopathological reversal effects of SYXZ on gastric dysplasia, alongside improvements in serum biomarkers, TCM syndrome scores, endoscopic risk stratification, psychological status, and systemic inflammation, thereby clarifying its therapeutic potential and safety profile for CAG with LGD.
Conclusions:
This study aims to rigorously evaluate the clinical efficacy and safety of SYXZ for CAG with LGD, generating evidence to guide its clinical implementation and protocol optimization. Key words：chronic atrophic gastritis with low-grade dysplasia, Shenye Xiaozheng Formula, randomized controlled trial, Traditional Chinese medicine Clinical Trial: chronic atrophic gastritis with low-grade dysplasia; Shenye Xiaozheng Formula; randomized controlled trial; Traditional Chinese medicine
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.